These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402 [TBL] [Abstract][Full Text] [Related]
31. Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial. Mayer KA; Budde K; Halloran PF; Doberer K; Rostaing L; Eskandary F; Christamentl A; Wahrmann M; Regele H; Schranz S; Ely S; Firbas C; Schörgenhofer C; Kainz A; Loupy A; Härtle S; Boxhammer R; Jilma B; Böhmig GA Trials; 2022 Apr; 23(1):270. PubMed ID: 35395951 [TBL] [Abstract][Full Text] [Related]
32. A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation. Vincenti F; Klintmalm G; Yang H; Ram Peddi V; Blahunka P; Conkle A; Santos V; Holman J Am J Transplant; 2020 Jan; 20(1):172-180. PubMed ID: 31397943 [TBL] [Abstract][Full Text] [Related]
33. Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study. Matignon M; Pilon C; Commereuc M; Grondin C; Leibler C; Kofman T; Audard V; Cohen J; Canoui-Poitrine F; Grimbert P PLoS One; 2017; 12(6):e0178572. PubMed ID: 28654684 [TBL] [Abstract][Full Text] [Related]
34. Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Jordan SC; Toyoda M; Vo AA Expert Rev Clin Immunol; 2011 May; 7(3):341-8. PubMed ID: 21595600 [TBL] [Abstract][Full Text] [Related]
35. Successful renal transplant outcome after intravenous gamma-globulin treatment of a highly sensitized pediatric recipient. Al-Uzri AY; Seltz B; Yorgin PD; Spier CM; Andreoni K Pediatr Transplant; 2002 Apr; 6(2):161-5. PubMed ID: 12000474 [TBL] [Abstract][Full Text] [Related]
36. An open label clinical trial of complement inhibition in multifocal motor neuropathy. Fitzpatrick AM; Mann CA; Barry S; Brennan K; Overell JR; Willison HJ J Peripher Nerv Syst; 2011 Jun; 16(2):84-91. PubMed ID: 21692905 [TBL] [Abstract][Full Text] [Related]
37. Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Luke PP; Scantlebury VP; Jordan ML; Vivas CA; Hakala TR; Jain A; Somani A; Fedorek S; Randhawa P; Shapiro R Transplantation; 2001 Aug; 72(3):419-22. PubMed ID: 11502969 [TBL] [Abstract][Full Text] [Related]
38. HLA Class Ia and Ib Polyreactive Anti-HLA-E IgG2a Monoclonal Antibodies (TFL-006 and TFL-007) Suppress Anti-HLA IgG Production by CD19+ B Cells and Proliferation of CD4+ T Cells While Upregulating Tregs. Ravindranath MH J Immunol Res; 2017; 2017():3475926. PubMed ID: 28634589 [TBL] [Abstract][Full Text] [Related]
39. Hyperimmune anti-COVID-19 IVIG (C-IVIG) Therapy for Passive Immunization of Severe and Critically Ill COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial. Ali S; Luxmi S; Anjum F; Muhaymin SM; Uddin SM; Ali A; Ali MR; Tauheed S; Khan M; Bajwa M; Baig SU; Shalim E; Ahmed I; Khan AS; Quraishy S Trials; 2020 Nov; 21(1):905. PubMed ID: 33138867 [TBL] [Abstract][Full Text] [Related]
40. Kinetics of cellular and humoral immunity in a successful case of positive crossmatch kidney transplantation: a case report. Tanimine N; Ide K; Yamashita M; Tanaka Y; Igarashi Y; Banshodani M; Tazawa H; Basnet NB; Doskali M; Onoe T; Tashiro H; Ohdan H Transplant Proc; 2011; 43(6):2411-4. PubMed ID: 21839279 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]